isirv Antiviral Group
News
Q4 / 2022 | Q3 / 2022 | Q2 / 2022 | Q1 / 2022 | Q1 / 2021 | Q3 / 2019 | Q2 / 2019 | ||||||||
Endonuclease Inhibitors
Effect of E23G/K, F36V, N37T, E119D, and E199G polymerase acidic protein substitutions on the replication and baloxavir susceptibility of influenza B viruses…read more
Chemical scaffold recycling: Structure-guided conversion of an HIV integrase inhibitor into a potent influenza virus RNA-dependent RNA polymerase inhibitor designed to minimize resistance potential…read more
Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PAN Endonuclease Inhibitors…read more
New Drug Discovery
Direct observation of backtracking by influenza A and B polymerases upon consecutive incorporation of the nucleoside analog T1106…read more
Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction…read more
Novel [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine and [1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine Derivatives: Synthesis, Anti-Viral In Vitro Study and Target Validation Activity…read more
Clinical Trials & Case Studies
Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials…read more
Methods
An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance…read more
Reviews
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy…read more
Influenza antivirals and their role in pandemic preparedness…read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA